Ovation Science 관리

관리 기준 확인 3/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Terry Howlett

최고 경영자

CA$124.8k

총 보상

CEO 급여 비율	92.0%
CEO 임기	7.1yrs
CEO 소유권	10.8%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Terry Howlett 의 보수는 Ovation Science 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-CA$637k
Mar 31 2024	n/a	n/a	-CA$823k
Dec 31 2023	CA$125k	CA$115k	-CA$813k
Sep 30 2023	n/a	n/a	-CA$794k
Jun 30 2023	n/a	n/a	-CA$800k
Mar 31 2023	n/a	n/a	-CA$752k
Dec 31 2022	CA$157k	CA$157k	-CA$794k
Sep 30 2022	n/a	n/a	-CA$2m
Jun 30 2022	n/a	n/a	-CA$2m
Mar 31 2022	n/a	n/a	-CA$2m
Dec 31 2021	CA$163k	CA$163k	-CA$2m
Sep 30 2021	n/a	n/a	-CA$801k
Jun 30 2021	n/a	n/a	-CA$848k
Mar 31 2021	n/a	n/a	-CA$1m
Dec 31 2020	CA$202k	CA$163k	-CA$1m
Sep 30 2020	n/a	n/a	-CA$1m
Jun 30 2020	n/a	n/a	-CA$1m
Mar 31 2020	n/a	n/a	-CA$759k
Dec 31 2019	CA$155k	CA$152k	-CA$836k
Sep 30 2019	n/a	n/a	-CA$739k
Jun 30 2019	n/a	n/a	-CA$678k
Mar 31 2019	n/a	n/a	-CA$615k
Dec 31 2018	CA$75k	CA$72k	-CA$508k
Dec 31 2017	CA$74k	CA$18k	-CA$148k

보상 대 시장: Terry 의 총 보상 ($USD 89.14K ) Canadian 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 169.13K ).

보상과 수익: Terry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Terry Howlett (76 yo)

7.1yrs

테뉴어

CA$124,750

보상

Mr. Terry H. Howlett has been the Chief Executive Officer and President of Skinvisible Inc. since March 5, 1998 and serves as its Chief Financial Officer and Principal Accounting Officer also served as its...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Terry Howlett	President	7.1yrs	CA$124.75k	10.83% CA$ 114.6k
Doreen McMorran	CFO, VP	7.1yrs	CA$101.80k	10.96% CA$ 115.9k
Joan Chypyha	Independent Director	6.8yrs	CA$12.00k	0.85% CA$ 9.0k
Shane Dungey	Independent Director	1.1yrs	CA$35.00k	데이터 없음
Ian Howard	Independent Director	6.8yrs	CA$12.00k	0.43% CA$ 4.5k
Ronald Stern	Independent Director	1.1yrs	CA$35.00k	데이터 없음

6.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: OVAT 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Ovation Science 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Ovation Science Inc., Annual General Meeting, Sep 20, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Ovation Science Inc., Annual General Meeting, Aug 22, 2023

Recent updates

New major risk - Financial position

Second quarter 2024 earnings released: CA$0.003 loss per share (vs CA$0.009 loss in 2Q 2023)

Less than half of directors are independent

Ovation Science Inc., Annual General Meeting, Sep 20, 2024

Full year 2023 earnings released: CA$0.027 loss per share (vs CA$0.027 loss in FY 2022)

Ovation Science Inc. announced that it has received $0.05 million in funding

Ovation Science Inc. announced that it expects to receive CAD 0.0675 million in funding

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2022)

New minor risk - Shareholder dilution

Ovation Science Inc. announced that it has received CAD 0.2 million in funding

Ovation Science Inc. announced that it expects to receive CAD 0.2 million in funding

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Ovation Science Inc., Annual General Meeting, Aug 22, 2023

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.027 loss per share (vs CA$0.081 loss in FY 2021)

Insufficient new directors

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)

Ovation Science Inc., Annual General Meeting, Oct 27, 2022

Insufficient new directors

First quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: CA$0.081 loss per share (vs CA$0.044 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.025 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.044 loss per share (vs CA$0.052 loss in FY 2019)

Ovation Science Inc. Enters into a Non-Exclusive Distribution Agreement for its DermSafe® Hand Sanitizer with CDMV

New 90-day low: CA$0.27

New 90-day low: CA$0.29

Third quarter 2020 earnings released: CA$0.01 loss per share

New 90-day low: CA$0.30

New 90-day low: CA$0.35

New 90-day low - CA$0.42

First half earnings released

Ovation Science Inc. (CNSX:OVAT) acquired World Rights to DermSafe® Hand Sanitizer from Skinvisible, Inc. (OTCPK:SKVI).

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령